Johnson & Johnson (JNJ) CFO Joseph Wolk talks about the strong second quarter performance, new products and the ongoing litigation over talc cancer allegations. He also discusses certain provisions of the Inflation Reduction Act that could hamper innovation and access to medicines. 
 
(MT Newswires)

Bloomberg videos